Mostrar el registro sencillo del ítem

dc.contributor.authorQuintanal-Villalonga, Alvaro 
dc.contributor.authorOjeda-Marquez, Laura 
dc.contributor.authorMarrugal, Ángela
dc.contributor.authorYagüe, Patricia
dc.contributor.authorPonce-Aix, Santiago
dc.contributor.authorSalinas, Ana
dc.contributor.authorCarnero, Amancio
dc.contributor.authorFerrer, Irene
dc.contributor.authorMolina-Pinelo, Sonia
dc.contributor.authorPaz Ares , Luis Gonzaga 
dc.date.accessioned2018-11-16T12:35:58Z
dc.date.available2018-11-16T12:35:58Z
dc.date.issued2018
dc.identifier.citationSci Rep. 2018; 8(1):2394.es_ES
dc.identifier.issn2045-2322es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6621
dc.description.abstractThe FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.es_ES
dc.description.sponsorshipThe authors thank the donors and the HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study. L.P.A. was funded by ISCIII (PI14/01964 and PIE15/00076), CIBER (CB16/12/00442) and RTICC (R12/0036/0028) and co-funded by European Union (ERDF/ESF, “Investing in your future”). The laboratory of A.C. was supported by grants from the Spanish Ministry of Economy and Competitiveness, PN I + D + I 2008-2011, PE I + D + I 2013-2016, ISCIII (PI15/00045 and CB16/12/00275), Consejeria de Ciencia e Innovacion (CTS-1848) and Consejeria de Salud of the Junta de Andalucia (PI-0096-2014). S.M.P. is funded by Consejería de Salud y Bienestar Social (PI- 0046-2012), ISCIII (PI17/00033) and co-funded by European Union (ERDF/ESF, “Investing in your future”), and Fundación Mutua Madrileña (2014). I.F. is funded by AECC (AIO2015) and Consejería de Igualdad, Salud y Políticas Sociales de la Junta de Andalucía (PI-0029-2013) and FIS (PI16/01311). A.Q. is funded by ISCIII (FI12/00429). L.O. is funded by Ministerio de Educación, Cultura y Deporte (FPU13/02595)es_ES
dc.language.isoenges_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectFACTOR RECEPTOR 4es_ES
dc.subjectEPITHELIAL-MESENCHYMAL TRANSITION;es_ES
dc.subjectFGFR4 GLY388ARG POLYMORPHISMes_ES
dc.subjectEXTRAHEPATIC CHOLANGIOCARCINOMA;es_ES
dc.subjectHEPATOCELLULAR-CARCINOMA;es_ES
dc.subjectPROGNOSTIC-SIGNIFICANCEes_ES
dc.subjectARG(388) ALLELEes_ES
dc.subjectSURVIVALes_ES
dc.subjectCELLSes_ES
dc.subjectSTAT3es_ES
dc.titleThe FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Inductiones_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29402970es_ES
dc.format.volume8es_ES
dc.format.number1es_ES
dc.format.page2394es_ES
dc.identifier.doi10.1038/s41598-018-20570-3es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.contributor.funderFundación Mutua Madrileña 
dc.contributor.funderRegional Government of Andalusia (España) 
dc.description.peerreviewed
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-018-20570-3.es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01964es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE15/00076es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI15/00045es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CB16/12/00275es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00033es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FI12/00429es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CB16/12/00442es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/R12/0036/0028es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CTS-1848es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0096-2014es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0046-2012es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI-0029-2013es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01311es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FPU13/02595es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional